Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BLD131
MIFTS: 61

Bladder Urothelial Carcinoma

Categories: Cancer diseases, Nephrological diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Bladder Urothelial Carcinoma

About this section

MalaCards integrated aliases for Bladder Urothelial Carcinoma:

Name: Bladder Urothelial Carcinoma 12 15
Transitional Cell Carcinoma of the Bladder 29 6
Transitional Cell Carcinoma of Bladder 12 71
Bladder Transitional Cell Carcinoma 12 17
Urinary Bladder Urothelial Carcinoma 12
Carcinoma Transitional Cell Bladder 54
Urothelial Bladder Carcinoma 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4006
NCIt 49 C39851
UMLS 71 C0279680
Sources

Summaries for Bladder Urothelial Carcinoma

About this section
Disease Ontology : 12 A bladder carcinoma that has material basis in transitional cells located in the lining of the bladder.

MalaCards based summary : Bladder Urothelial Carcinoma, also known as transitional cell carcinoma of the bladder, is related to bladder cancer and in situ carcinoma. An important gene associated with Bladder Urothelial Carcinoma is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Valrubicin and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include lining of the bladder, prostate and breast, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Bladder Urothelial Carcinoma

About this section

Diseases related to Bladder Urothelial Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 455)
# Related Disease Score Top Affiliating Genes
1 bladder cancer 32.2 TUG1 TP53 PVT1 PIK3CA NRAS MEG3
2 in situ carcinoma 32.0 TP53 HRAS ERBB2
3 transitional cell carcinoma 31.9 TP53 HRAS FGFR3 ERBB2 BRAF
4 squamous cell papilloma 31.5 TP53 HRAS
5 lynch syndrome 31.4 TP53 PIK3CA NRAS KRAS HRAS FGFR3
6 ureteral obstruction 31.2 TP53 NFE2L2 CTNNB1
7 vulva cancer 31.2 TP53 PIK3CA ERBB2
8 renal cell carcinoma, nonpapillary 31.2 TUG1 TP53 PVT1 PIK3CA NRAS MALAT1
9 carcinosarcoma 31.2 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
10 signet ring cell adenocarcinoma 31.2 TP53 KRAS HRAS ERBB2
11 undifferentiated pleomorphic sarcoma 31.2 PIK3CA KRAS IDH1
12 intrahepatic cholangiocarcinoma 31.2 TUG1 TP53 KRAS IDH1 ERBB2 CTNNB1
13 thyroid carcinoma 31.1 TP53 PIK3CA NRAS HRAS CTNNB1 BRAF
14 nevus, epidermal 31.1 PIK3CA NRAS KRAS HRAS FGFR3 FGFR1
15 adenoma 31.1 TP53 PIK3CA KRAS CTNNB1 BRAF
16 neurofibromatosis, type iv, of riccardi 31.1 TP53 KRAS HRAS
17 colorectal adenocarcinoma 31.1 TP53 KRAS HRAS ERBB2 CTNNB1 BRAF
18 colon adenocarcinoma 31.1 TP53 PIK3CA KRAS ERBB2 CTNNB1
19 large cell carcinoma 31.1 KRAS HRAS FGFR1 ERBB2
20 cholangiocarcinoma 31.1 TUG1 TP53 PIK3CA MALAT1 KRAS IDH1
21 villous adenoma 31.1 KRAS HRAS BRAF
22 mucinous adenocarcinoma 31.1 TP53 KRAS ERBB2
23 suppression of tumorigenicity 12 31.0 TP53 PIK3CA KRAS IDH1 HRAS FGFR1
24 exanthem 31.0 KRAS HRAS ERBB2
25 lymphoma 31.0 TP53 PVT1 PIK3CA NRAS GAS5 FGFR1
26 adenocarcinoma 31.0 TP53 PIK3CA MAP2K1 MALAT1 KRAS HRAS
27 gastric adenocarcinoma 30.9 TP53 PIK3CA NRAS KRAS HRAS HOTAIR
28 squamous cell carcinoma 30.9 TUG1 TP53 PIK3CA NFE2L2 MAP2K1 MALAT1
29 thyroid cancer, nonmedullary, 1 30.9 MALAT1 HOTAIR GAS5 CRNDE BRAF
30 pancreatic adenocarcinoma 30.9 TP53 PIK3CA MAP2K1 KRAS HRAS FGFR1
31 non-invasive bladder papillary urothelial neoplasm 30.9 TP53 FGFR3
32 prostate cancer 30.9 TUG1 TP53 PVT1 PIK3CA NFE2L2 MEG3
33 appendix adenocarcinoma 30.8 KRAS HRAS
34 breast cancer 30.8 TUG1 TP53 PVT1 PIK3CA NRAS MEG3
35 cervical cancer 30.7 TUG1 TP53 PVT1 PIK3CA NFE2L2 MEG3
36 glioma 30.7 TP53 PVT1 PIK3CA MEG3 MALAT1 IDH1
37 pancreatic cancer 30.6 TUG1 TP53 PVT1 PIK3CA MEG3 MAP2K1
38 colorectal cancer 30.4 TUG1 TP53 PVT1 PIK3CA NRAS NFE2L2
39 hepatocellular carcinoma 30.4 TUG1 TP53 PVT1 PIK3CA NRAS NFE2L2
40 non-papillary transitional cell carcinoma of the bladder 12.7
41 infiltrating bladder urothelial carcinoma sarcomatoid variant 12.6
42 non-invasive bladder urothelial carcinoma 12.5
43 clear cell variant infiltrating bladder urothelial carcinoma 12.5
44 micropapillary variant infiltrating bladder urothelial carcinoma 12.5
45 lipid-cell variant infiltrating bladder urothelial carcinoma 12.5
46 plasmacytoid variant infiltrating bladder urothelial carcinoma 12.5
47 nested variant infiltrating bladder urothelial carcinoma 12.5
48 microcystic variant infiltrating bladder urothelial carcinoma 12.5
49 lymphoma-like variant infiltrating bladder urothelial carcinoma 12.4
50 invasive bladder transitional cell carcinoma 11.9

Graphical network of the top 20 diseases related to Bladder Urothelial Carcinoma:



Diseases related to Bladder Urothelial Carcinoma
Sources

Symptoms & Phenotypes for Bladder Urothelial Carcinoma

About this section

GenomeRNAi Phenotypes related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

26 (show all 46)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.83 HRAS KRAS PIK3CA BRAF
2 Decreased viability GR00106-A-0 10.83 KRAS
3 Decreased viability GR00107-A-1 10.83 MAP2K1
4 Decreased viability GR00221-A-1 10.83 FGFR1 FGFR3 HRAS KRAS PIK3CA NRAS
5 Decreased viability GR00221-A-2 10.83 FGFR1 FGFR3 HRAS KRAS PIK3CA
6 Decreased viability GR00221-A-3 10.83 FGFR3 HRAS ERBB2 MAP2K1 NRAS
7 Decreased viability GR00221-A-4 10.83 PIK3CA BRAF ERBB2
8 Decreased viability GR00301-A 10.83 KRAS BRAF
9 Decreased viability GR00342-S-1 10.83 MAP2K1
10 Decreased viability GR00342-S-2 10.83 MAP2K1
11 Decreased viability GR00342-S-3 10.83 MAP2K1
12 Decreased viability GR00381-A-1 10.83 KRAS BRAF
13 Decreased viability GR00402-S-2 10.83 FGFR1 FGFR3 HRAS KRAS PIK3CA BRAF
14 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.87 FGFR1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.87 BRAF
16 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.87 CTNNB1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.87 FGFR1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.87 FGFR1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.87 IDH1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-136 9.87 IDH1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.87 IDH1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.87 IDH1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.87 BRAF
24 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.87 BRAF
25 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.87 FGFR1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.87 BRAF CTNNB1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.87 FGFR1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-191 9.87 CTNNB1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.87 BRAF
30 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.87 CTNNB1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-26 9.87 FGFR1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.87 BRAF
33 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.87 BRAF
34 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.87 BRAF
35 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.87 IDH1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.87 FGFR1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.87 BRAF CTNNB1 FGFR1 IDH1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.87 CTNNB1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.87 FGFR1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.87 CTNNB1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.87 CTNNB1 FGFR1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.87 CTNNB1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.87 FGFR1
44 Decreased cell migration GR00055-A-1 9.8 BRAF CTNNB1 FGFR3 HRAS KRAS PIK3CA
45 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.65 CTNNB1 ERBB2 FGFR3 HRAS NRAS
46 Increased cell migration GR00055-A-3 9.35 BRAF CTNNB1 HRAS KRAS PIK3CA

MGI Mouse Phenotypes related to Bladder Urothelial Carcinoma:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.36 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
2 cardiovascular system MP:0005385 10.34 BRAF CTNNB1 ERBB2 FGFR1 HRAS KRAS
3 homeostasis/metabolism MP:0005376 10.34 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
4 cellular MP:0005384 10.33 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 KRAS
5 craniofacial MP:0005382 10.32 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
6 digestive/alimentary MP:0005381 10.32 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
7 integument MP:0010771 10.29 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
8 mortality/aging MP:0010768 10.29 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
9 embryo MP:0005380 10.27 BRAF CTNNB1 ERBB2 FGFR1 KRAS MAP2K1
10 endocrine/exocrine gland MP:0005379 10.26 BRAF CTNNB1 ERBB2 FGFR1 HRAS KRAS
11 neoplasm MP:0002006 10.2 BRAF CTNNB1 ERBB2 FGFR3 HRAS KRAS
12 nervous system MP:0003631 10.17 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
13 normal MP:0002873 10.11 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
14 limbs/digits/tail MP:0005371 10.1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 KRAS
15 hearing/vestibular/ear MP:0005377 10.08 BRAF CTNNB1 FGFR1 FGFR3 KRAS MAP2K1
16 no phenotypic analysis MP:0003012 10.01 CTNNB1 FGFR1 FGFR3 HRAS KRAS NRAS
17 renal/urinary system MP:0005367 9.86 BRAF CTNNB1 FGFR1 FGFR3 HRAS KRAS
18 respiratory system MP:0005388 9.81 BRAF CTNNB1 ERBB2 FGFR3 HRAS IDH1
19 skeleton MP:0005390 9.77 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
20 pigmentation MP:0001186 9.72 BRAF CTNNB1 KRAS NRAS TP53
21 vision/eye MP:0005391 9.28 BRAF CTNNB1 FGFR1 FGFR3 KRAS MAP2K1
Sources

Drugs & Therapeutics for Bladder Urothelial Carcinoma

About this section

Drugs for Bladder Urothelial Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 157)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valrubicin Approved Phase 3 56124-62-0 41744
2
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
3
Amphotericin B Approved, Investigational Phase 2, Phase 3 1397-89-3 14956 5280965
4
Aminolevulinic acid Approved Phase 3 106-60-5 137
5
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
6
Lenograstim Approved, Investigational Phase 3 135968-09-1
7
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
8
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
9
Pembrolizumab Approved Phase 3 1374853-91-4
10
ramucirumab Approved, Investigational Phase 3 947687-13-0
11
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
12
Cephalexin Approved, Investigational, Vet_approved Phase 3 15686-71-2 27447
13
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
14
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
15
leucovorin Approved Phase 3 58-05-9 6006 143
16
Vinblastine Approved Phase 3 865-21-4 13342 241903
17
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
18
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
19
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
20
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
22 Tocotrienol Investigational Phase 3 6829-55-6
23
Levulinic acid Experimental Phase 3 123-76-2 11579
24
Fenretinide Investigational Phase 3 65646-68-6
25
BCG vaccine Investigational Phase 3
26 Tocopherols Phase 3
27 Tocotrienols Phase 3
28 Liposomal amphotericin B Phase 2, Phase 3
29 Antiparasitic Agents Phase 3
30 Antiprotozoal Agents Phase 3
31 Photosensitizing Agents Phase 3
32 Vitamins Phase 3
33 Antioxidants Phase 3
34 Vitamin B3 Phase 3
35 Hypolipidemic Agents Phase 3
36 Lipid Regulating Agents Phase 3
37 Nicotinic Acids Phase 3
38 Vasodilator Agents Phase 3
39 Antineoplastic Agents, Immunological Phase 3
40 Vaccines Phase 3
41 Pharmaceutical Solutions Phase 3
42 Dermatologic Agents Phase 3
43 Cytochrome P-450 Enzyme Inhibitors Phase 3
44 Anti-Bacterial Agents Phase 3
45 Antibiotics, Antitubercular Phase 3
46 Topoisomerase Inhibitors Phase 3
47 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
48 Fluoroquinolones Phase 3
49 Folic Acid Antagonists Phase 3
50 Vitamin B Complex Phase 3

Interventional clinical trials:

(show top 50) (show all 195)
# Name Status NCT ID Phase Drugs
1 Adjuvant vs. Progression-Triggered Treatment With Gemcitabine After Radical Cystectomy for Locally Advanced Transitional Cell Carcinoma of the Bladder in Patients Not Suitable for Cisplatin-Based Chemotherapy - A Phase 3 Study Unknown status NCT00146276 Phase 3 gemcitabine
2 Phase III Randomized Study of a Single Adjunctive Instillation of Intravesical AD 32 (N-Trifluoroacetyladriamycin-14-valerate) Versus No Adjunctive Therapy Immediately Following Transurethral Resection in Patients With Multiple Superficial (Ta/T1) Bladder Tumors Unknown status NCT00003725 Phase 3 valrubicin
3 Phase III Study Of Adjuvant Cisplatin-Gemcitabine Vs. Observation After Radical Cystectomy In High-Risk Bladder Cancer Unknown status NCT00054626 Phase 3 cisplatin;gemcitabine hydrochloride
4 Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [TREATMENT] Unknown status NCT00553345 Phase 3 selenium;vitamin E
5 Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) Unknown status NCT00553124 Phase 3 selenium;vitamin E
6 A Phase II/III, Randomised, Two-Arm, Comparison of Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With HER1 and/or HER2 Overexpressing Locally Advanced or Metastatic Bladder Cancer [LaMB] Unknown status NCT00949455 Phase 2, Phase 3 lapatinib ditosylate
7 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3 Amino levulinic Acid
8 Phase III Randomized, Double-Blind Study of DFMO vs. Placebo in Low Grade Superficial Bladder Cancer Completed NCT00003814 Phase 3 eflornithine
9 Megadose Vitamins as Chemoprevention of Transitional Cell Carcinoma of the Bladder Completed NCT00003623 Phase 3
10 Phase III Randomized Chemoprevention Study of Selenium on the Recurrence of Non-invasive Bladder Cancer Completed NCT00729287 Phase 3
11 Phase III Study Comparing Sequential Chemotherapy (AG-ITP) To Cisplatin And Gemcitabine As Adjuvant Treatment After Cystectomy For Transitional Cell Carcinoma Of The Bladder Completed NCT00014534 Phase 3 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride
12 Randomised Trial of Selective Bladder Preservation Against Radical Excision (Cystectomy) in Muscle Invasive T2/T3 Transitional Cell Carcinoma of the Bladder - Feasibility Study Completed NCT00867347 Phase 3
13 A Multicenter Randomized Trial of Radical Radiotherapy With Carbogen in the Radical Treatment of Locally Advanced Bladder Cancer Completed NCT00033436 Phase 3 carbogen
14 A Phase III Randomized Trial of Either M-VAC or Paclitaxel + Carboplatin as Postoperative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High-Risk for Relapse Completed NCT00003701 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate
15 A RANDOMIZED TRIAL OF RADICAL RADIOTHERAPY IN pT1G3 NXM0 BLADDER CANCER Completed NCT00002490 Phase 3 mitomycin C
16 Randomized Phase III Trial Comparing Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients With pT3-pT4, and/or N+M0 Transitional Cell Carcinoma (TCC) of the Bladder Completed NCT00028756 Phase 3 doxorubicin hydrochloride;gemcitabine hydrochloride;vinblastine sulfate;methotrexate;cisplatin
17 Phase IIb/III Chemoprevention Trial of Celecoxib to Prevent Recurrence of Superficial Bladder Cancer Completed NCT00006124 Phase 2, Phase 3 celecoxib;placebo
18 Randomized Chemoprevention Trial With 4-HPR (Fenretinide) in Superficial Bladder Cancer Completed NCT00004154 Phase 3 Fenretinide
19 2X2 Factorial Randomized Phase III Study Comparing Standard Versus Reduced Volume Radiotherapy With and Without Synchronous Chemotherapy in Muscle Invasive Bladder Cancer Completed NCT00024349 Phase 3 fluorouracil;mitomycin C
20 Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients With Metastatic or Locally Advanced Urothelial Cancer Without Prior Systemic Therapy Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
21 Phase III Trial of Methotrexate, Vinblastine, Doxorubicin and Cisplatin vs Carboplatin and Paclitaxel in Advanced Carcinoma of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
22 Comparative Study of Intravesical BCG Standard Dose Long-Term Maintenance Versus BCG 1/3 Dose Long-Term Maintenance Versus BCG Standard Dose Short-Term Maintenance Versus BCG 1/3 Dose Short-Term Maintenance in Intermediate and High Risk Ta, T1 Papillary Carcinoma of the Urinary Bladder Completed NCT00002990 Phase 3
23 Cabazitaxel in Platinum Pre-treated Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma Who Developed Disease Progression Within 12 Months of Platinum Based Chemotherapy. Completed NCT01668459 Phase 2, Phase 3 Cabazitaxel
24 A Phase III Blinded Study of Immediate Post TURBT Instillation of Gemcitabine Versus Saline in Patients With Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer Completed NCT00445601 Phase 3 gemcitabine hydrochloride
25 Randomized Phase II/III Study Assessing Gemcitabine/Carboplatin And Methotrexate/Carboplatin/Vinblastine In Previously Untreated Patients With Advanced Urothelial Cancer Ineligible For Cisplatin Based Chemotherapy Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
26 Sequential Bacillus Calmette-Guérin and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin Alone for High Risk Superficial Bladder Cancer: a Prospective Randomised Study Completed NCT01442519 Phase 3 electromotive mitomycin
27 S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer Recruiting NCT03091660 Phase 3
28 Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation Recruiting NCT03244384 Phase 3
29 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy Active, not recruiting NCT02426125 Phase 3 Ramucirumab;Docetaxel;Placebo
30 The Effect of Fluoroquinolones on the Disease-Free Interval in Patients With Stage Ta Transitional Cell Carcinoma of the Bladder Terminated NCT00003824 Phase 3 cephalexin;Ciprofloxacin
31 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Multicenter Study of Immediate Postoperative Instillation of Gemcitabine in Patients With Superficial Transitional Cell Carcinoma of the Bladder Terminated NCT00191477 Phase 3 Gemcitabine;Placebo
32 A Phase III Study of IRESSA in Combination With Intravesical BCG Versus Intravesical BCG Alone in High Risk Superficial Transitional Cell Carcinoma of the Bladder Terminated NCT00352079 Phase 3 gefitinib
33 Chemoresection With 4 Weekly Intravesical Instillations Of Mitomycin C Versus Transurethral Resection (TUR) Followed By One Single Immediate Instillation Of Mitomycin C In Single, Small, Papillary Stage Ta, T1 Bladder Tumors: A Prospective Randomized Phase III Trial Terminated NCT00042887 Phase 3 mitomycin C
34 MVAC (Methotrexate, Vinblastine, Adriamycin, and Cisplatin) in Organ-Confined Bladder Cancer Based on p53 Status Terminated NCT00005047 Phase 3 cisplatin;doxorubicin hydrochloride;methotrexate;vinblastine
35 A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB) Terminated NCT00384891 Phase 3 Bacillus Calmette-Guérin
36 A Phase II Trial of Combination Cabazitaxel and Cisplatin Chemotherapy in the Neo-adjuvant Treatment of Transitional Cell Carcinoma of the Urinary Bladder Unknown status NCT01616875 Phase 2 Cabazitaxel + Cisplatin chemotherapy
37 First Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma of the Bladder With a Combination of Cisplatin-Paclitaxel-Gemcitabine Unknown status NCT00006118 Phase 2 cisplatin;gemcitabine hydrochloride;paclitaxel
38 A Phase II Study of Neoadjuvant Cisplatin and Gemcitabine Plus Sorafenib for Patients With Transitional-Cell Carcinoma of the Bladder Unknown status NCT01222676 Phase 2 cisplatin;gemcitabine hydrochloride;sorafenib tosylate
39 A Phase II Study of Tesetaxel in Subjects Previously Treated With Chemotherapy for Metastatic Transitional Cell Carcinoma of the Urothelium Unknown status NCT01215877 Phase 2 Tesetaxel
40 Treatment of Patients With Transitional-Cell Carcinoma of the Urothelial Tract With Gemcitabine, Docetaxel and Filgrastim Unknown status NCT00005958 Phase 2 docetaxel;gemcitabine hydrochloride
41 A Phase II Study Assessing SU-011248 in Previously Untreated Patients With Advanced Urothelial Cancer Ineligible for Cisplatin-Based Chemotherapy Unknown status NCT01118039 Phase 2 sunitinib malate
42 Bladder Cancer: Open Versus Laparoscopic or Robotic Cystectomy. A Study to Determine the Feasibility of Randomization to Open Versus Minimal Access Cystectomy in Patients With Bladder Cancer. Unknown status NCT01196403 Phase 2
43 Phase II Study of the Fully Human Monoclonal Antibody Against Transforming Growth Factor-beta (TGFβ) Receptor ALK1 (PF-03446962) in Relapsed or Refractory Urothelial Cancer (UC) Failing First-line Treatment. Unknown status NCT01620970 Phase 2 PF03446962
44 A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
45 A Phase II Study of R115777 (Zarnestra) in Superficial Transitional Cell Carcinoma of Bladder Completed NCT00047216 Phase 2 tipifarnib
46 A Phase 2 Study of the Aurora Kinase A Inhibitor Alisertib (MLN8237) in Patients With Relapsed or Refractory Transitional-cell Carcinoma of the Bladder and Urothelial Tract Completed NCT02109328 Phase 2 Alisertib;Paclitaxel;Placebo
47 Prospective Phase II Randomized Trial of Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer Completed NCT01824329 Phase 2
48 Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Transitional Cell Carcinoma of the Bladder Completed NCT00136175 Phase 2 Paclitaxel;Carboplatin;Gemcitabine
49 Phase II Study of Intravesical Therapy With AD 32 in Patients With Papillary Urothelial Carcinoma or Carcinoma in Situ (CIS) Refractory to Prior Therapy With Bacillus Calmette-Guerin Completed NCT00003129 Phase 2 valrubicin
50 PHASE II TRIAL OF THE COMBINATION OF TRANSURETHRAL RESECTION AND NEOADJUVANT CHEMOTHERAPY FOR PATIENTS WITH INVASIVE UROTHELIAL TRACT TUMORS SELECTED BY STAGE AND P53 NUCLEAR EXPRESSION Completed NCT00002919 Phase 2 cisplatin;doxorubicin hydrochloride;methotrexate;vinblastine sulfate

Search NIH Clinical Center for Bladder Urothelial Carcinoma

Sources

Genetic Tests for Bladder Urothelial Carcinoma

About this section

Genetic tests related to Bladder Urothelial Carcinoma:

# Genetic test Affiliating Genes
1 Transitional Cell Carcinoma of the Bladder 29
Sources

Anatomical Context for Bladder Urothelial Carcinoma

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Urothelial Carcinoma:

19
Lining Of The Bladder

MalaCards organs/tissues related to Bladder Urothelial Carcinoma:

40
Prostate, Breast, Lung, Lymph Node, Testes, Thyroid, Kidney
Sources

Publications for Bladder Urothelial Carcinoma

About this section

Articles related to Bladder Urothelial Carcinoma:

(show top 50) (show all 2687)
# Title Authors PMID Year
1
Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. 54 61
17311305 2007
2
Adenoviral receptor expression of normal bladder and transitional cell carcinoma of the bladder. 54 61
17293658 2007
3
Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. 54 61
15733109 2005
4
[Multivariate analysis of recurrence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 and Ki67]. 54 61
12731328 2003
5
Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. 54 61
11696726 2001
6
Expression of pS2 protein and its relation with the Ki-67 proliferative indices and tumor recurrence in superficial bladder carcinomas. 54 61
11528193 2001
7
E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. 54 61
11342899 2001
8
The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. 54 61
10687971 2000
9
Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. 54 61
10699635 2000
10
p53 and c-jun expression in urinary bladder transitional cell carcinoma: correlation with proliferating cell nuclear antigen (PCNA) histological grade and clinical stage. 54 61
9187909 1997
11
[Detection and clinical pathological significance of the expression of P21, P185, p53 proteins and mutation of ras, p53 genes in transitional cell carcinoma of the bladder]. 54 61
9275651 1996
12
Expression of p53 product in Chinese human bladder carcinoma. 54 61
7688167 1993
13
Enterovesical fistula secondary to transitional cell carcinoma of the bladder in a 20 years old patient: A rare entity. 61
32025495 2020
14
Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma. 61
31596511 2020
15
The clinicopathological characteristics and prognostic value of squamous differentiation in patients with bladder urothelial carcinoma: a meta-analysis. 61
31011874 2020
16
Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. 61
31843338 2020
17
Targeting FGFR in bladder cancer: ready for clinical practice? 61
31671027 2020
18
Case Study: Landscape of Chimeric RNAs in Bladder Cancer. 61
31728975 2020
19
Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes. 61
31996725 2020
20
Phenotypical and potential functional characteristics of different immune cells expressing CD28H/B7-H5 and their relationship with cancer prognosis. 61
31901178 2020
21
SPAG5-AS1 inhibited autophagy and aggravated apoptosis of podocytes via SPAG5/AKT/mTOR pathway. 61
31957155 2020
22
Cutaneous metastasis of bladder urothelial carcinoma. 61
31788428 2020
23
[Interest of reTURB for pTa high grade bladder urothelial carcinoma]. 61
31866142 2020
24
Identification of five long noncoding RNAs signature and risk score for prognosis of bladder urothelial carcinoma. 61
31373406 2020
25
A radiogenomics signature for predicting the clinical outcome of bladder urothelial carcinoma. 61
31396730 2020
26
Slingshot homolog-1 expression is a poor prognostic factor of pT1 bladder urothelial carcinoma after transurethral resection. 61
31965287 2020
27
Amplification-driven BCL6-suppressed cytostasis is mediated by transrepression of FOXO3 and post-translational modifications of FOXO3 in urinary bladder urothelial carcinoma. 61
31903146 2020
28
Differential Effect of Sex on Outcomes After Radical Surgery for Upper Tract and Bladder Urothelial Carcinoma: A Systematic Review and Meta-Analysis. 61
31995432 2020
29
The Landscape of Long Non-Coding RNA Dysregulation and Clinical Relevance in Muscle Invasive Bladder Urothelial Carcinoma. 61
31810243 2019
30
Effects of Epigallocatechin Gallate (EGCG) on Urinary Bladder Urothelial Carcinoma-Next-Generation Sequencing and Bioinformatics Approaches. 61
31805718 2019
31
Development of a novel six-long noncoding RNA signature predicting survival of patients with bladder urothelial carcinoma. 61
31338862 2019
32
[Roles of Programmed Cell Death-1/Programmed Cell Death-ligand 1 and Cytotoxic T-lymphocyte-associated Protein 4 Signaling Pathways in Bladder Urothelial Carcinoma]. 61
31907140 2019
33
Indoleamine-2,3-dioxygenase-1 expression predicts poorer survival and up-regulates ZEB2 expression in human early stage bladder cancer. 61
31253481 2019
34
Increased Incidence of Lung Cancer Among Patients With Superficial Transitional Cell Carcinoma: A Potential Risk Cohort for Lung Cancer Screening. 61
31303453 2019
35
Down-regulated RBM5 inhibits bladder cancer cell apoptosis by initiating an miR-432-5p/β-catenin feedback loop. 61
31318608 2019
36
Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma. 61
31028363 2019
37
Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA. 61
31607216 2019
38
The Deubiquitinating Enzyme Inhibitor PR-619 Enhances the Cytotoxicity of Cisplatin via the Suppression of Anti-Apoptotic Bcl-2 Protein: In Vitro and In Vivo Study. 61
31627336 2019
39
Surgical approach as a determinant factor of clinical outcome following radical cystectomy: Does Enhanced Recovery After Surgery (ERAS) level the playing field? 61
31285114 2019
40
Genomic Analysis and Treatment Response of a Bladder Urothelial Carcinoma With Sarcomatoid Variant Histology. 61
31239241 2019
41
Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis. 61
31493109 2019
42
Re: Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. 61
31184534 2019
43
Early Oncological and Functional Outcomes of Prostate Capsule Sparing Cystectomy Compared with Standard Radical Cystectomy. 61
31579223 2019
44
Diagnosis of urinary bladder urothelial carcinoma by immunocytology with p53, MCM5, MCM2 and Ki-67 antibodies using cell blocks derived from urine. 61
30943322 2019
45
Bilateral Diffuse Uveal Melanocytic Proliferation Associated With Bladder Cancer: A Novel Imaging Finding. 61
31415702 2019
46
Narrow-band imaging assisted cystoscopy in the follow-up of patients with transitional cell carcinoma of the bladder: a randomized study in comparison with white light cystoscopy. 61
31471739 2019
47
Prognostic value and reproducibility of different microscopic characteristics in the WHO grading systems for pTa and pT1 urinary bladder urothelial carcinomas. 61
31412916 2019
48
The Occurrence of Metronidazole-Induced Encephalopathy in Cancer Patients: A Hospital-Based Retrospective Study. 61
31359955 2019
49
Lynch syndrome and urologic malignancies: a contemporary review. 61
31045926 2019
50
MRS1754 inhibits proliferation and migration of bladder urothelial carcinoma by regulating mitogen-activated protein kinase pathway. 61
30565699 2019
Sources

Variations for Bladder Urothelial Carcinoma

About this section

ClinVar genetic disease variations for Bladder Urothelial Carcinoma:

6 (show top 50) (show all 276) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 IDH1 NM_005896.3(IDH1):c.395G>A (p.Arg132His)SNV Pathogenic 156444 rs121913500 2:209113112-209113112 2:208248388-208248388
2 TP53 NM_000546.5(TP53):c.856G>A (p.Glu286Lys)SNV Pathogenic 183752 rs786201059 17:7577082-7577082 17:7673764-7673764
3 TP53 NM_000546.5(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
4 TP53 NM_000546.5(TP53):c.733G>T (p.Gly245Cys)SNV Pathogenic 12349 rs28934575 17:7577548-7577548 17:7674230-7674230
5 TP53 NM_000546.5(TP53):c.725G>A (p.Cys242Tyr)SNV Pathogenic 12354 rs121912655 17:7577556-7577556 17:7674238-7674238
6 TP53 NM_000546.5(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
7 TP53 NM_000546.5(TP53):c.659A>C (p.Tyr220Ser)SNV Pathogenic 12383 rs121912666 17:7578190-7578190 17:7674872-7674872
8 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
9 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
10 HRAS NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)SNV Pathogenic 12606 rs104894228 11:534286-534286 11:534286-534286
11 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
12 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
13 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)SNV Pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
14 TP53 NM_000546.5(TP53):c.733G>A (p.Gly245Ser)SNV Pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230
15 TP53 NM_000546.5(TP53):c.818G>A (p.Arg273His)SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
16 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
17 FGFR3 NM_000142.4(FGFR3):c.746C>G (p.Ser249Cys)SNV Pathogenic 16339 rs121913483 4:1803568-1803568 4:1801841-1801841
18 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg)SNV Pathogenic 13900 rs11554290 1:115256529-115256529 1:114713908-114713908
19 NRAS NM_002524.5(NRAS):c.38G>A (p.Gly13Asp)SNV Pathogenic 13901 rs121434596 1:115258744-115258744 1:114716123-114716123
20 BRAF NM_004333.6(BRAF):c.1405G>C (p.Gly469Arg)SNV Pathogenic 13970 rs121913357 7:140481403-140481403 7:140781603-140781603
21 BRAF NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala)SNV Pathogenic 13971 rs121913355 7:140481402-140481402 7:140781602-140781602
22 BRAF NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly)SNV Pathogenic 13972 rs121913338 7:140453154-140453154 7:140753354-140753354
23 BRAF NM_004333.6(BRAF):c.1406G>A (p.Gly469Glu)SNV Pathogenic 13974 rs121913355 7:140481402-140481402 7:140781602-140781602
24 FGFR3 NM_000142.4(FGFR3):c.742C>T (p.Arg248Cys)SNV Pathogenic 16332 rs121913482 4:1803564-1803564 4:1801837-1801837
25 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
26 BRAF NM_004333.6(BRAF):c.1787G>T (p.Gly596Val)SNV Pathogenic 40387 rs397507483 7:140453148-140453148 7:140753348-140753348
27 BRAF NM_004333.6(BRAF):c.1406G>T (p.Gly469Val)SNV Pathogenic 44803 rs121913355 7:140481402-140481402 7:140781602-140781602
28 PIK3CA NM_006218.4(PIK3CA):c.1637A>G (p.Gln546Arg)SNV Pathogenic 45466 rs397517201 3:178936095-178936095 3:179218307-179218307
29 TP53 NM_000546.5(TP53):c.638G>A (p.Arg213Gln)SNV Pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
30 TP53 NM_000546.5(TP53):c.844C>G (p.Arg282Gly)SNV Pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
31 TP53 NM_000546.5(TP53):c.842A>G (p.Asp281Gly)SNV Pathogenic 141141 rs587781525 17:7577096-7577096 17:7673778-7673778
32 TP53 NM_000546.5(TP53):c.659A>G (p.Tyr220Cys)SNV Pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
33 TP53 NM_000546.5(TP53):c.743G>T (p.Arg248Leu)SNV Pathogenic 230253 rs11540652 17:7577538-7577538 17:7674220-7674220
34 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro)SNV Pathogenic 280409 rs11554290 1:115256529-115256529 1:114713908-114713908
35 NRAS NM_002524.5(NRAS):c.183A>T (p.Gln61His)SNV Pathogenic 373003 rs121913255 1:115256528-115256528 1:114713907-114713907
36 PIK3CA NM_006218.4(PIK3CA):c.1357G>A (p.Glu453Lys)SNV Pathogenic 376470 rs1057519925 3:178928079-178928079 3:179210291-179210291
37 PIK3CA NM_006218.4(PIK3CA):c.2176G>A (p.Glu726Lys)SNV Pathogenic 376476 rs867262025 3:178938934-178938934 3:179221146-179221146
38 TP53 NM_000546.5(TP53):c.713G>T (p.Cys238Phe)SNV Pathogenic 376574 rs730882005 17:7577568-7577568 17:7674250-7674250
39 TP53 NM_000546.5(TP53):c.712T>C (p.Cys238Arg)SNV Pathogenic 376576 rs1057519981 17:7577569-7577569 17:7674251-7674251
40 TP53 NM_000546.5(TP53):c.578A>C (p.His193Pro)SNV Pathogenic 376612 rs786201838 17:7578271-7578271 17:7674953-7674953
41 TP53 NM_000546.5(TP53):c.841G>T (p.Asp281Tyr)SNV Pathogenic 376585 rs764146326 17:7577097-7577097 17:7673779-7673779
42 TP53 NM_000546.5(TP53):c.841G>A (p.Asp281Asn)SNV Pathogenic 376586 rs764146326 17:7577097-7577097 17:7673779-7673779
43 TP53 NM_000546.5(TP53):c.818G>T (p.Arg273Leu)SNV Pathogenic 376655 rs28934576 17:7577120-7577120 17:7673802-7673802
44 TP53 NM_000546.5(TP53):c.817C>A (p.Arg273Ser)SNV Pathogenic/Likely pathogenic 376656 rs121913343 17:7577121-7577121 17:7673803-7673803
45 TP53 NM_000546.5(TP53):c.523C>G (p.Arg175Gly)SNV Pathogenic/Likely pathogenic 376649 rs138729528 17:7578407-7578407 17:7675089-7675089
46 TP53 NM_000546.5(TP53):c.845G>C (p.Arg282Pro)SNV Pathogenic/Likely pathogenic 376659 rs730882008 17:7577093-7577093 17:7673775-7673775
47 TP53 NM_000546.5(TP53):c.700T>C (p.Tyr234His)SNV Pathogenic/Likely pathogenic 376691 rs864622237 17:7577581-7577581 17:7674263-7674263
48 NFE2L2 NM_006164.5(NFE2L2):c.235G>A (p.Glu79Lys)SNV Pathogenic/Likely pathogenic 376466 rs1057519922 2:178098810-178098810 2:177234082-177234082
49 PIK3CA NM_006218.4(PIK3CA):c.1624G>C (p.Glu542Gln)SNV Pathogenic/Likely pathogenic 376244 rs121913273 3:178936082-178936082 3:179218294-179218294
50 NRAS NM_002524.5(NRAS):c.182A>T (p.Gln61Leu)SNV Pathogenic/Likely pathogenic 375874 rs11554290 1:115256529-115256529 1:114713908-114713908
Sources

Expression for Bladder Urothelial Carcinoma

About this section
Search GEO for disease gene expression data for Bladder Urothelial Carcinoma.
Sources

Pathways for Bladder Urothelial Carcinoma

About this section

Pathways related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 161)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.18 TP53 PIK3CA NRAS MAP2K1 KRAS IDH1
2
ERK Signaling 63
Show member pathways
 13.97 TP53 NRAS MAP2K1 KRAS HRAS FGFR3
3
HIV Life Cycle 65
Show member pathways
 13.88 PIK3CA NRAS MAP2K1 KRAS IDH1 HRAS
4
GPCR Pathway 63
Show member pathways
 13.83 TP53 NRAS MAP2K1 KRAS HRAS FGFR3
5
PEDF Induced Signaling 63
Show member pathways
 13.81 TP53 NRAS MAP2K1 KRAS HRAS FGFR3
6
Activation of cAMP-Dependent PKA 63
Show member pathways
 13.7 NRAS MAP2K1 KRAS HRAS FGFR3 FGFR1
7
TGF-Beta Pathway 63
Show member pathways
 13.7 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
8
Developmental Biology 65
Show member pathways
 13.66 PIK3CA NRAS MAP2K1 KRAS HRAS FGFR3
9
Class I MHC mediated antigen processing and presentation 65
Show member pathways
 13.59 TP53 PIK3CA NRAS KRAS HRAS FGFR3
10
Cytokine Signaling in Immune system 65
Show member pathways
 13.52 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
11
CREB Pathway 63
Show member pathways
 13.44 NRAS MAP2K1 KRAS HRAS FGFR3 FGFR1
12
Nanog in Mammalian ESC Pluripotency 63
Show member pathways
 13.44 NRAS MAP2K1 KRAS HRAS FGFR3 FGFR1
13
PAK Pathway 63
Show member pathways
 13.42 NRAS KRAS HRAS FGFR3 FGFR1 ERBB2
14
IL-2 Pathway 63
Show member pathways
 13.35 TP53 NRAS MAP2K1 KRAS HRAS ERBB2
15
Toll-like Receptor Signaling Pathway 1 36
Show member pathways
 13.29 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
16
Phospholipase-C Pathway 63
Show member pathways
 13.23 TP53 NRAS MAP2K1 KRAS HRAS FGFR3
17
p70S6K Signaling 63
Show member pathways
 13.17 NRAS MAP2K1 KRAS HRAS FGFR3 FGFR1
18
G-Beta Gamma Signaling 63
Show member pathways
 13.16 NRAS MAP2K1 KRAS HRAS CTNNB1 BRAF
19
fMLP Pathway 63
Show member pathways
 13.16 TP53 NRAS MAP2K1 KRAS HRAS CTNNB1
20
PI3K-Akt signaling pathway 36
Show member pathways
 13.14 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
21
TNFR1 Pathway 63
Show member pathways
 13.11 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
22
Human cytomegalovirus infection 36
Show member pathways
 13.11 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
23
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 13.08 PIK3CA NRAS MAP2K1 KRAS HRAS ERBB2
24
Focal Adhesion 1 36
Show member pathways
 13.08 PIK3CA NRAS MAP2K1 KRAS HRAS ERBB2
25
Sertoli-Sertoli Cell Junction Dynamics 63
Show member pathways
 13.07 NRAS MAP2K1 KRAS HRAS CTNNB1 BRAF
26
Aldosterone synthesis and secretion 36
Show member pathways
 13.05 NRAS MAP2K1 KRAS HRAS CTNNB1 BRAF
27
NFAT and Cardiac Hypertrophy 63
Show member pathways
 13.05 PIK3CA NRAS MAP2K1 KRAS HRAS FGFR3
28
CCR5 Pathway in Macrophages 63
Show member pathways
 13.03 PIK3CA NRAS MAP2K1 KRAS HRAS BRAF
29
Downstream signaling of activated FGFR2 65
Show member pathways
 13.02 PIK3CA NRAS KRAS HRAS FGFR3 FGFR1
30
Endometrial cancer 36
Show member pathways
 13.02 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
31
Development Angiotensin activation of ERK 22
Show member pathways
 13.01 PIK3CA NRAS MAP2K1 KRAS HRAS BRAF
32
MAPK-Erk Pathway 66
Show member pathways
 12.99 PIK3CA NRAS MAP2K1 KRAS HRAS BRAF
33
Apoptosis Modulation and Signaling 1
Show member pathways
 12.97 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
34
Beta-Adrenergic Signaling 63
Show member pathways
 12.96 NRAS MAP2K1 KRAS HRAS CTNNB1 BRAF
35
MAPK signaling pathway 36 1
12.94 TP53 NRAS MAP2K1 KRAS HRAS FGFR3
36
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.91 TP53 PIK3CA NRAS KRAS HRAS FGFR3
37
Ras signaling pathway 36
Show member pathways
 12.9 PIK3CA NRAS MAP2K1 KRAS HRAS FGFR3
38
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.89 PIK3CA MAP2K1 KRAS HRAS BRAF
39
Circadian entrainment 36
Show member pathways
 12.89 PIK3CA NRAS MAP2K1 KRAS HRAS
40
Development HGF signaling pathway 22
Show member pathways
 12.88 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
41
Gastric cancer 36
Show member pathways
 12.86 TP53 PIK3CA NRAS NFE2L2 MAP2K1 KRAS
42
4-1BB Pathway 63
Show member pathways
 12.84 TP53 NRAS MAP2K1 KRAS HRAS BRAF
43
Glioma 36
Show member pathways
 12.83 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
44
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.82 PIK3CA NRAS MAP2K1 KRAS HRAS CTNNB1
45
Regulation of actin cytoskeleton 36 1
12.82 PIK3CA NRAS MAP2K1 KRAS HRAS FGFR3
46
Relaxin signaling pathway 36
Show member pathways
 12.8 PIK3CA NRAS MAP2K1 KRAS HRAS
47
G-AlphaQ Signaling 63
Show member pathways
 12.8 NRAS MAP2K1 KRAS HRAS BRAF
48
Immune response IL-23 signaling pathway 22
Show member pathways
 12.78 TP53 PIK3CA NRAS KRAS HRAS ERBB2
49
ErbB signaling pathway 1 36
Show member pathways
 12.77 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
50
Negative regulation of FGFR3 signaling 65
Show member pathways
 12.76 PIK3CA NRAS KRAS HRAS FGFR3 FGFR1
Sources

GO Terms for Bladder Urothelial Carcinoma

About this section

Biological processes related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 10.01 PIK3CA MAP2K1 FGFR3 FGFR1 ERBB2 BRAF
2 protein phosphorylation GO:0006468 9.95 PIK3CA MAP2K1 FGFR3 FGFR1 ERBB2 BRAF
3 heart development GO:0007507 9.92 TP53 MAP2K1 ERBB2 CTNNB1
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 MAP2K1 HRAS FGFR3 BRAF
5 positive regulation of cell proliferation GO:0008284 9.91 KRAS HRAS FGFR3 FGFR1 ERBB2 CTNNB1
6 regulation of cell proliferation GO:0042127 9.88 TP53 FGFR1 CTNNB1 BRAF
7 positive regulation of protein kinase B signaling GO:0051897 9.81 PIK3CA FGFR3 FGFR1 ERBB2
8 negative regulation of gene expression GO:0010629 9.8 TP53 MAP2K1 HRAS FGFR1 CTNNB1
9 cellular response to drug GO:0035690 9.77 TP53 NFE2L2 BRAF
10 negative regulation of neuron apoptotic process GO:0043524 9.76 PIK3CA KRAS HRAS BRAF
11 thymus development GO:0048538 9.67 MAP2K1 CTNNB1 BRAF
12 Ras protein signal transduction GO:0007265 9.67 TP53 NRAS KRAS HRAS
13 peptidyl-tyrosine phosphorylation GO:0018108 9.65 MAP2K1 FGFR3 FGFR1 ERBB2 BRAF
14 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.62 TP53 MAP2K1
15 positive regulation of MAP kinase activity GO:0043406 9.62 KRAS HRAS FGFR1 ERBB2
16 positive regulation of phospholipase activity GO:0010518 9.61 FGFR3 FGFR1
17 lung-associated mesenchyme development GO:0060484 9.59 FGFR1 CTNNB1
18 regulation of axon regeneration GO:0048679 9.58 MAP2K1 BRAF
19 trachea formation GO:0060440 9.57 MAP2K1 CTNNB1
20 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.56 TP53 NFE2L2
21 positive regulation of gene expression GO:0010628 9.56 TP53 NFE2L2 MAP2K1 KRAS HRAS ERBB2
22 response to isolation stress GO:0035900 9.55 KRAS HRAS
23 positive regulation of MAPK cascade GO:0043410 9.55 HRAS FGFR3 FGFR1 ERBB2 CTNNB1
24 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.52 TP53 NFE2L2
25 MAPK cascade GO:0000165 9.23 NRAS MAP2K1 KRAS HRAS FGFR3 FGFR1

Molecular functions related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.88 PIK3CA MAP2K1 FGFR3 FGFR1 ERBB2 BRAF
2 protein phosphatase binding GO:0019903 9.65 TP53 ERBB2 CTNNB1
3 GDP binding GO:0019003 9.63 NRAS KRAS HRAS
4 protein C-terminus binding GO:0008022 9.55 TP53 MAP2K1 HRAS ERBB2 CTNNB1
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.54 FGFR3 FGFR1 ERBB2
6 RNA polymerase II activating transcription factor binding GO:0001102 9.5 TP53 NFE2L2 CTNNB1
7 transcription cofactor binding GO:0001221 9.43 TP53 NFE2L2
8 protein tyrosine kinase activity GO:0004713 9.35 MAP2K1 FGFR3 FGFR1 ERBB2 BRAF
9 fibroblast growth factor-activated receptor activity GO:0005007 9.26 FGFR3 FGFR1
10 nucleotide binding GO:0000166 9.23 NRAS MAP2K1 KRAS HRAS FGFR3 FGFR1
Sources

Sources for Bladder Urothelial Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....